No Detail Found!

Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-based Regimens.

Author(s)
Amir Sattar DeInstitute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Misbah Masood DeInstitute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Hasan Nisar Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad, Pakistan
Ismat Fatima DeInstitute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Ahmad Farooq DeInstitute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Abu Baker Shahid DeInstitute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan
Abstract
Objective: To determine the disease characteristics of testicular germ cell tumor, biochemical/radiological response to chemotherapy and common toxicity profile. Study Design: Case series. Place and Duration of Study: Institute of Nuclear Medicine and Oncology (INMOL), Lahore, from January 2010 to December 2013. Methodology: Fifty-one patients with histologically proven testicular germ cell tumor, who fulfilled the pre-defined eligibility criteria, were selected. Presenting symptoms and disease stage were studied. Patients were staged according to the AJCC 2010 staging criteria and prognosis was classified according to the IGCCCG Classification of Metastatic Germ Cell Cancer. Initial chemotherapy treatment was based upon the International Germ Cell Consensus Classification, 1997. Patients were also evaluated for chemotherapy-induced toxicity based on Common Toxicology Criteria version 4. SPSS version 16.0 was used for statistical analysis. Results: Main presenting symptoms included testicular pain (37.3%), testicular swelling (25.5%), and abdominopelvic pain (11.8%). Most of the patients had mixed germ cell histology (p <0.001) and presented with advanced disease stage. Out of 51 patients, 41 (80.3%) achieved complete clinical remission after first line chemotherapy. All patients having complete response achieved 2-year survival and 37 (90.2%) had no evidence of recurrent disease. Four patients with recurrent disease achieved complete remission with second line chemotherapy. Five (9.8%) had partial response after first line chemotherapy while 2 (3.9%) progressed on treatment. All patients developed alopecia, 21 (41.1%) experienced other toxicities which were managed symptomatically and with minor dose modifications. Conclusion: Many patients with germ cell tumors presented with pain, and in an advanced stage, with mixed histology. Overall response rate was 90.2% with platinum-based chemotherapy.
Publication Details
Page(s) 292-296
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 4, Year: 2018

Request the full text from PASTIC

References
HeinzelbeckerJ,KatzmarzikM,Weiss C, 2013.During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival,Int Braz J Urol 39 10 -21
MeeksJJ,SheinfeldJ,EggenerSE, 2012.Environmental toxicology of testicular cancer,Urol Oncol 30 212 -5
EinhornL, 1990.Treatment of testicular cancer: a new and improved model,J Clin Oncol 8 1777 -81
BokemeyerC,KollmannsbergerC,Stenning S, 2004.Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials,Br J Cancer 91 683 -7
Garcia-del-MuroX,MarotoP,GumàJ, 2008.Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish germ cell cancer group study,J Clin Oncol 2 5416 -21
TravisLB,FossaSD,SchonfeldSJ, 2005.576 testicular cancer patients: focus on long-term survivor,J Natl Cancer Inst 97 1354 -65
SteinerH,MüllerT,GozziC, 2006.Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours,B J U Int 98 349 -52
HaugnesHS,WethalT,AassN., 2010.Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study,J Clin Oncol 28 4649 -57
KatherineAM,SusanSD,AliceJS, 2003.Trends in the incidence of testicular germ cell tumors in the United States,Cancer 97 63 -70
LoehrerPJ,GoninR,NicholsCR, 1998.Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor,J Clin Oncol 16 2500 -04
McCaffreyJA,MazumdarM,Bajorin DF, .Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival,J Clin Oncol 199 2559 -63
KondaguntaGV,BacikJ,DonadioA, 2005.Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors,J Clin Oncol 2 6549 -55
BajorinDF,SarosdyMF,PfisterDG, 1993.Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study,J Clin Oncol 11 598 -606
HorwichA,SleijferDT,FossaSD, 1997.Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional medical research council/European organization for research and treatment of cancer tria,J Clin Oncol 15 1844 -52
De WitR,RobertsJT,WilkinsonPM, 2001.Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council,J Clin Oncol 19 1629 -40
TonerGC,StocklerMR,Boyer MJ, 2001.Comparison of two standard chemotherapy regimens for good-prognosis germcell tumours: a randomised trial,Australian and New Zealand Germ Cell Trial Grou. Lancet 357 739 -45
CulineS,KerbratP,KramarA, 2007.Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP,Ann Oncol 18 917 -24
DaugaardG,NielsenH,BruunB., 1993.Infections in patients treated with high-dose chemotherapy for germ cell tumours,Eur J Cancer 29 2220 -2
HansenSW,Helweg-LarsenS,TrojaborgW, 1989.Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer,J Clin Oncol 7 1457 -61
BokemeyerC,BergerCC,KuczykMA, 1996.Evaluation of long-term toxicity after chemotherapy for testicular cancer,J Clin Oncol 14 2923 -32
0

Citations

0

Downloads

66

Views